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Abstract
Background: Systematic reviews are pivotal components in the development of evidence-based clinical guidelines.
To evaluate the methodological quality of these systematic reviews, several tools have been proposed. Among
them, the assessment of multiple systematic reviews (AMSTAR) checklist is probably used most frequently. This tool
comprises 11 items related to the steps taken when conducting a systematic review, and it is claimed to have good
face and content validity. The objective of this debate paper was twofold: (a) to critically evaluate the ability of all
AMSTAR checklist items to adequately determine the methodological quality of a systematic review; and (b) to
describe difficulties regarding interpretation of the checklist, and provide potential solutions for these difficulties.
Discussion: Some items of the AMSTAR checklist seem to assess the quality of reporting of a systematic review
more than its methodological quality. For example, item 7 may not “capture” the true methodological quality of
primary studies included in the systematic review. Item 10 does not likely result in the collection of in-depth
information on the presence of publication bias in the systematic review. Furthermore, some items may be difficult
to interpret, hindering accurate assessment. For example, item 5 does not explicitly indicate whether a list of
documents excluded in each phase of selection (i.e., after evaluation of titles and abstracts, and after full-text
assessment) should be reported.
Summary: The present debate paper evaluated and discussed some methodological limitations of the AMSTAR
checklist, as well as challenges involved in evaluation of the checklist’s items. Several suggestions are also made to
optimize the use of this checklist. The information in this paper may stimulate further discussion among systematic
reviewers, methodologists and clinicians.
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Background
Systematic reviews (SRs) are important components in
the decision-making process in clinical practice. For ex-
ample, SRs of randomized controlled trials (RCTs) form
the basis for the development of clinical guidelines for
interventions. Thus, evaluation of the methodological
quality of a systematic review is crucial to avoid the de-
velopment of a clinical guideline based on potentially
misleading information.
Several tools have been developed to evaluate the meth-
odological quality of a systematic review. Currently, the
assessment of multiple systematic reviews (AMSTAR)
checklist [1] appears to be among the most frequently used
tools. A quick search of MEDLINE (via PubMed) using
the key word “AMSTAR” on 14 March 2015 retrieved
200 documents, most of which described the use of this
checklist to evaluate the methodological quality of SRs
published in a great variety of medical disciplines. The
AMSTAR checklist comprises 11 items related directly
to the necessary steps taken when performing a system-
atic review. It is claimed to have good face and content
validity for measuring the methodological quality of
SRs that include only RCTs [1]. Currently, AMSTAR
authors are developing a version of the checklist for the
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Although the AMSTAR checklist has been validated
and used consistently since its publication in 2007, dif-
ferentiation of whether it evaluates the quality of
reporting or the methodological quality of a systematic
review can be difficult. Quality of reporting is related
strictly to what is reported in the published text, and
thus increases with the completeness of an article.
Methodological quality is a broader term that involves
different concepts such as internal, external, construct,
and descriptive validity [3]. Nevertheless, the ways in
which AMSTAR items were developed and have been
evaluated raise questions about whether this tool can
“capture” the methodological quality of SRs evaluated.
In addition, although the authors of the AMSTAR
checklist explicitly state the rationale for the inclusion
of each item, clear guidance on the use of the items to
evaluate a systematic review is lacking in some cases.
AMSTAR checklist items are presented in the form of
questions, with possible responses of YES (item/ques-
tion fully addressed), NO (item/question not addressed),
CANNOT ANSWER (not enough information to answer
the question), and NOT APPLICABLE. The AMSTAR
checklist was not originally intended to provide quanti-
tative scores, and one can argue that this more subject-
ive evaluation of items might reduce the reliability and
replicability of measurements. Another group of re-
searchers developed a revision of the AMSTAR checklist
(R-AMSTAR) with quantitative item scoring [4]. How-
ever, adequate weighting of items according to relative
importance to provide a final score is arguably difficult.
Some evidence suggests that the measurement proper-
ties of the R-AMSTAR need to be studied further [5].
Thus, the question of whether the content validity of the
checklist should involve quantitative measures remains
open. The present work focuses exclusively on the
AMSTAR checklist.
The main purpose of this debate paper is to critically
evaluate the ability of all AMSTAR checklist items to
adequately determine the methodological quality of a
systematic review. A secondary objective is to describe
challenges regarding interpretation of the checklist, and
present potential solutions to these challenges. AMSTAR
checklist items and guiding notes (taken from the
AMSTAR home page) [2] are presented below in italics,
followed by critical evaluations. The notes do not appear
on the original checklist [1].
Discussion
1. Was an ‘a priori’ design provided? The research ques-
tion and inclusion criteria should be established before
the conduct of the review. Note: Need to refer to a proto-
col, ethics approval, or pre-determined/a priori published
research objectives to score a “yes.”
The text of the item appears to be clear. When a sys-
tematic review does not describe the research question
and inclusion criteria, the assessor should record a NO
response. However, the note is not sufficiently clear for
adequate evaluation, as reference to “pre-determined/a
priori published research objectives” is sufficient for a
score of YES. What about the reporting of detailed eligi-
bility criteria? This item is important for the evaluation
of potential deviations in the protocol, which would
imply in some sort of “selective outcome reporting” [6].
Thus, to clarify this item, the note should also require
reference to a priori inclusion/exclusion criteria.
2. Was there duplicate study selection and data extrac-
tion? There should be at least two independent data
extractors and a consensus procedure for disagreements
should be in place. Note: 2 people do study selection, 2
people do data extraction, consensus process or one per-
son checks the other’s work.
Consensus means that assessors reach general agree-
ment on a specific issue, whereas the note states that
this requirement can be fulfilled when one assessor
“checks the other’s work.” Thus, this explanation im-
plies that consensus must not necessarily be achieved,
in apparent contradiction of the item 2 text. One may
argue that only checking the work of the first assessor
may bias the evaluation of the assessor performing this
check. Therefore, the phrase “or one person checks the
other’s work” should be deleted from the note to re-
solve this issue.
3. Was a comprehensive literature search performed?
At least two electronic sources should be searched. The
report must include years and databases used (e.g., Central,
EMBASE, and MEDLINE). Key words and/or MESH
terms must be stated and where feasible the search
strategy should be provided. All searches should be sup-
plemented by consulting current contents, reviews, text-
books, specialized registers, or experts in the particular
field of study, and by reviewing the references in the
studies found. Note: If at least 2 sources + one supple-
mentary strategy used, select “yes” (Cochrane register/
Central counts as 2 sources; a grey literature search
counts as supplementary).
Because lists of publications do not match perfectly
among databases [7], a search of at least 2 electronic
databases seems to be important to increase compre-
hensiveness (interestingly, new evidence suggests that
the benefits for searching sources beyond one major
database such as MEDLINE may be modest [8]). Sup-
plementary strategies may complement the potential
lack of comprehensiveness of electronic searches. This
item does not clearly identify “hand-searching” as a
supplementary strategy. Hand-searching, as defined by
the Cochrane Collaboration, is the “planned searching
of a journal page by page (i.e. by hand), including
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editorials and letters, to identify all reported RCTs and
NON-RCTs” [7]. Thus, hand-searching should be
listed explicitly in the item. Furthermore, the number
of supplementary strategies seems to be selected arbi-
trarily. Data on the minimum number of such sources re-
quired for a comprehensive search strategy are probably
lacking, but comprehensiveness would arguably increase
with the number of supplementary sources searched.
Thus, to increase comprehensiveness, use of at least 2
supplementary strategies should be recommended.
4. Was the status of publication (i.e. grey literature)
used as an inclusion criterion? The authors should state
that they searched for reports regardless of their publica-
tion type. The authors should state whether or not they
excluded any reports (from the systematic review), based
on their publication status, language etc. Note: If review
indicates that there was a search for “grey literature” or
“unpublished literature,” indicate “yes.” SINGLE database,
dissertations, conference proceedings, and trial registries
are all considered grey for this purpose. If searching a
source that contains both grey and non-grey, must
specify that they were searching for grey/unpublished lit.
This item seems to be informative and clear. The main
concern is the number of sources used to search the
grey literature. The question of whether a search of a
single source results in a sufficiently comprehensive re-
trieval of unpublished information remains. Thus, as
stipulated in item 3 for the searching of electronic data-
bases, this item should recommend that at least 2
sources be searched to meet this criterion, to increase
the comprehensiveness of searches for unpublished
material.
5. Was a list of studies (included and excluded) pro-
vided? A list of included and excluded studies should be
provided. Note: Acceptable if the excluded studies are
referenced. If there is an electronic link to the list but the
link is dead, select “no.”
In a systematic review, the process of document se-
lection (inclusion and exclusion) is performed in two
phases: (a) the evaluation of titles and abstracts,
followed by (b) the evaluation of full texts. In these 2
phases, documents that meet the eligibility criteria are
included and those that do not are excluded. This
checklist item does not clearly indicate whether the list
of studies should be derived from the first or second
phase. To improve transparency and clarity, the check-
list should make this differentiation. Most SRs involv-
ing large numbers of initially selected papers report a
full list of papers excluded after full-text evaluation.
Nevertheless, to enable reproducibility of all systematic
review steps, documents excluded in the first and
second phases of selection should be listed, with rea-
sons for exclusion. Most scientific journals now allow
authors to provide such information, which is often
lengthy and cannot be published in printed format, in
online appendices.
6. Were the characteristics of the included studies pro-
vided? In an aggregated form such as a table, data from
the original studies should be provided on the partici-
pants, interventions and outcomes. The ranges of char-
acteristics in all the studies analyzed e.g., age, race, sex,
relevant socioeconomic data, disease status, duration,
severity, or other diseases should be reported. Note: Ac-
ceptable if not in table format as long as they are
described as above.
Among AMSTAR items, this item probably receives
the largest number of YES responses across disciplines.
Most SRs include tables describing the features of pri-
mary studies included. The challenge related to this item
is the establishment of a threshold for the minimum
amount of information (i.e., number of characteristics)
required for a YES response. Such a threshold could be
established, with characteristics that are applicable in
most disciplines, to facilitate the use of the item and
increase the homogeneity of assessment. Nevertheless,
this strategy might imply less comprehensive evaluation
due to the lack of opportunity for more subjective judg-
ments, although less experienced systematic reviewers
will benefit from more defined and clearer guidance.
7. Was the scientific quality of the included studies
assessed and documented? ‘A priori’ methods of assess-
ment should be provided (e.g., for effectiveness studies if
the author(s) chose to include only randomized, double-
blind, placebo controlled studies, or allocation conceal-
ment as inclusion criteria); for other types of studies
alternative items will be relevant. Note: Can include use
of a quality scoring tool or checklist, e.g., Jadad scale, risk
of bias, sensitivity analysis, etc., or a description of qual-
ity items, with some kind of result for EACH study (“low”
or “high” is fine, as long as it is clear which studies
scored “low” and which scored “high”; a summary score/
range for all studies is not acceptable).
The main concern with this item is whether good
reporting represents true methodological quality. For
example, one may argue that inclusion of a “description
of quality items, with some kind of result” does not rep-
resent adequate evaluation of primary studies. Some
tools for evaluation of the quality of evidence listed in
this item, such as the Jadad scale [9], have received criti-
cism because they seem to be related more to reporting
than to quality. Furthermore, the Jadad scale contains no
mention of allocation concealment, which is important
in the evaluation of an RCT’s internal validity. Another
situation of concern is authors’ use of the incorrect tool
to evaluate primary studies, such as the application of a
tool used to evaluate RCTs to the evaluation of studies
with other designs, such as retrospective cohort studies.
At times, systematic review authors include primary
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studies with several designs; in these cases, the appropri-
ate tool should be used for each type of study. Thus, the
tool (s) used to evaluate the quality/risk of bias (ROB) of
primary studies included in a systematic review should
be sufficiently comprehensive to reflect the true quality
of these studies. One such instrument is the Cochrane
Collaboration’s ROB tool [10], which enables the evalu-
ation of important domains related directly to the in-
ternal validity of an RCT and may capture the strengths
and weaknesses of primary studies included. Another tool
is the GRADE approach [11], which enables evaluation of
the overall quality of evidence and includes ROB among
the domains assessed. The GRADE approach is becom-
ing universally used and has been proposed for the
development of evidence-based guidelines [12]. Accept-
ance of these tools as standards for the evaluation of
primary trials would increase the homogeneity of com-
parison/evaluation among SRs from the same discipline.
8. Was the scientific quality of the included studies
used appropriately in formulating conclusions? The re-
sults of the methodological rigor and scientific quality
should be considered in the analysis and the conclusions
of the review, and explicitly stated in formulating rec-
ommendations. Note: Might say something such as “the
results should be interpreted with caution due to poor
quality of included studies.” Cannot score “yes” for this
question if scored “no” for question 7.
This item demonstrates the importance of using a
good approach for item 7, as the 2 items are intercon-
nected. When authors fail to clearly report the quality
measures mentioned in item 7, item 8 will be assigned a
NO response. Although detailed information about the
quality of primary studies may be difficult to convey in a
systematic review, the use of sentences such as “the re-
sults should be interpreted with caution due to poor
quality of included studies” may not be sufficient. Thus,
the checklist could be improved by establishing a mini-
mum (and higher-level) threshold for the reporting of
detailed information, such as by requiring more specific
information from systematic review authors on (a) how
the quality/ROB of studies affected treatment effect esti-
mates; and (b) whether the quality/ROB scores were in-
corporated in meta-analytic estimates (for meta-analyses).
If authors did not incorporate the quality/ROB in the
results, they should provide an explanation.
9. Were the methods used to combine the findings of
studies appropriate? For the pooled results, a test should
be done to ensure the studies were combinable, to assess
their homogeneity (i.e., Chi-squared test for homogeneity,
I2). If heterogeneity exists a random effects model
should be used and/or the clinical appropriateness of
combining should be taken into consideration (i.e., is it
sensible to combine?). Note: Indicate “yes” if they men-
tion or describe heterogeneity, i.e., if they explain that
they cannot pool because of heterogeneity/variability be-
tween interventions.
This item reflects a good rationale: when conducting
SRs, assessors should first evaluate the feasibility of
combining results in a meta-analysis. Then, they should
consider the statistical test performed by the authors to
determine the degree of heterogeneity. In the presence
of heterogeneity, a random model should be used and
heterogeneity should be evaluated at the clinical level.
Then, assessors should determine whether systematic
review authors conducted meta-analyses properly. The
concern with this item is the recommendation to assess
the use of a random model “and/or” evaluation of clin-
ical heterogeneity, which allows for item fulfillment
based on accounting for only one type of heterogeneity.
Although statistical heterogeneity may also involve clin-
ical heterogeneity [13], the assessor should carefully
evaluate the presence of both types of heterogeneity in
determining the sensibility of combining results. Thus,
the word “or” should be deleted from the sentence.
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a
combination of graphical aids (e.g., funnel plot, other
available tests) and/or statistical tests (e.g., Egger regres-
sion test, Hedges-Olken). Note: If no test values or funnel
plot included, score “no”. Score “yes” if mentions that
publication bias could not be assessed because there
were fewer than 10 included studies.
This item is another case in which the quality of
reporting should not be used as a proxy for methodo-
logical quality. For example, the item indicates that the
authors of a meta-analysis including fewer than 10
studies are not obligated to report any statistical exam-
ination of publication bias, very likely because of the
“lack of power” of statistical tests to detect this bias
[14]. Thus, reporting on non-evaluation of the risk of
publication bias because of a small sample constitutes
fulfillment of this item. However, the systematic review
is not necessarily free of publication bias. Thus, “high-
quality” reporting may not be translated directly into
high methodological quality.
The first sentence of this item should be changed to
“was the systematic review at high risk of publication
bias?” This revision would lead to evaluation based on
authors’ description of this risk (e.g., as high or low),
even in SRs involving small numbers of studies. In
other words, a YES response would require systematic
review authors to report perceived risk of publication
bias, with a strong argument/rationale to support this
statement.
11. Was the conflict of interest included? Potential
sources of support should be clearly acknowledged in
both the systematic review and the included studies.
Note: To get a “yes,” must indicate source of funding or
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support for the systematic review AND for each of the
included studies.
This item does not clearly indicate whether the conflict
of interest (COI) of a researcher or any person directly
involved in a systematic review should be reported. The
question “was the conflict of interest included?” does not
specify who should declare the COI, and the note sug-
gests that reporting of sources of funding or support for
the systematic review and primary studies is sufficient.
Thus, this item should be clarified to enable more in-
depth assessment. A YES response should require report-
ing of COI for all persons involved in the studies and
sources of funding. COI involves, for example, a strong
relationship between study participants and the enter-
prise(s) supporting the study (e.g., researchers owning
stocks in a company or serving on its board).
Summary
This debate paper presents a critical appraisal of the
characteristics of the AMSTAR checklist, a validated and
recognized tool for the evaluation of the methodological
quality of SRs. Some challenges of assessment have been
described from the point of view of the assessor, and po-
tential solutions to improve the reliability of the tool and
homogeneity of its use have been offered. The paper will
ideally generate further discussion among systematic re-
viewers and methodologists aiming to optimize the use
of the AMSTAR checklist.
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